Headlines

Regeneron Pharmaceuticals (REGN) Q4 2025 (USD): Adj. EPS 11.44 (exp. 10.56), Revenue 3.88bln (exp. 3.78bln)

Newsquawk Staff ·

Regeneron Pharmaceuticals (REGN) Q4 2025 (USD): Adj. EPS 11.44 (exp. 10.56), Revenue 3.88bln (exp. 3.78bln)

What it means

Regeneron Pharmaceuticals reported stronger-than-expected Q4 2025 results, with adjusted EPS surpassing expectations and revenue also above consensus. This beat could enhance investor sentiment, particularly in the biotech sector, indicating robust demand for their products. Given the positive results, expect potential upward revisions in earnings estimates and a favorable impact on the stock and sector performance.

Related headlines